The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Cryptococcosis diagnosis and treatment: What do we know now
Open accessAbstract
Cryptococcosis has evolved into a major invasive fungal disease over the last century. Its primary epidemiology has been focused on three major outbreaks of disease that reflects both changing environmental exposures and growth of host risk factors. The molecular understandings of yeast pathobiology have been bolstered by identification of the yeast's dynamic genomic structures and functions. It is during these new insights into epidemiology and pathobiology that we have also improved our diagnosis of this infection with a new point-of-care, simple, cheap test which utilizes a lateral flow assay for antigen detection. With methods for effective identification of Cryptococcus in the host, the principles for management of this deadly infection include both use of old drugs and new insights into treatment strategies to improve outcome. In this review there are a series of recent insights, opinions, and facts which attempt to summarize our present knowledge base for this deadly fungal central nervous system infection with a particular emphasis on its diagnosis and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationSionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479 · cited 1×
“Second, the dynamic mechanism of heteroresistance to fluconazole in Cryptococcus spp. that has been elegantly described (Sionov et al., 2010) has now importantly been shown to be relevant in vivo (Sionov et al., 2013).”
BackgroundJarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367 · cited 14×
“Given that high fungal burden and a poor CSF pro-inflammatory response (together with high chemokine levels) pre-ART have both been shown to be risk factors for IRIS (Boulware et al., 2010; Jarvis et al., 2014), a practical point may to use a combination of CSF quantitative cryptococcal cultures and CSF white cell cou…”
BackgroundInfluentialSelf-citationEpidemiology of cryptococcal meningitis in the US: 1997–2009
Pyrgos, V., Seitz, A. E., Steiner, C. A., Prevots, D. R., & Williamson, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056269 · Cited by 309
Jarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290 · cited 2×
“These patients may now be identified and cases prevented with preART screening and treatment of asymptomatic cryptococcal antigenemia with high dose fluconazole (Jarvis et al., 2012).”
BackgroundSelf-citationAncient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest
Hagen, F., Ceresini, P. C., Polacheck, I., Ma, H., Nieuwerburgh, F. V., Gabaldón, T., Kagan, S., Pursall, E. R., Hoogveld, H. L., van Iersel, L. J. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071148 · Cited by 218
Engelthaler, D. M., Hicks, N. D., Gillece, J. D., Roe, C. C., Schupp, J. M., Driebe, E. M., Gilgado, F., Carriconde, F., Trilles, L., Firacative, C., et al. (2014) · mBio · doi:10.1128/mbio.01464-14 · Cited by 133
Sionov, E., Chang, Y. C., & Kwon-Chung, K. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00694-13 · Cited by 112
Billmyre, R. B., Croll, D., Li, W., Mieczkowski, P., Carter, D. A., Cuomo, C. A., Kronstad, J. W., & Heitman, J. (2014) · mBio · doi:10.1128/mbio.01494-14 · Cited by 90
Jackson, A. T., Nussbaum, J. C., Phulusa, J., Namarika, D., Chikasema, M., Kanyemba, C., Jarvis, J. N., Jaffar, S., Hosseinipour, M. C., van der Horst, C., et al. (2012) · AIDS · doi:10.1097/qad.0b013e328354b419 · Cited by 86 · cited 1×
“…offer a compromise, with animal model and human data demonstrating similar rates of fungal clearance from the central nervous system in the second week following treatment that is compatible with the drug’s long half-life (Jackson et al., 2012; Livermore et al., 2013; Muzoora et al., 2012).”
Background
Cited by
Maziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
Self-citationThreats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture
Fisher, M. C., Gurr, S. J., Cuomo, C. A., Blehert, D. S., Jin, H., Stukenbrock, E. H., Stajich, J. E., Kahmann, R., Boone, C., Denning, D. W., et al. (2020) · mBio · doi:10.1128/mbio.00449-20 · Cited by 536
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Pulmonary cryptococcosis: A review of pathobiology and clinical aspects
Setianingrum, F., Rautemaa-Richardson, R., & Denning, D. W. (2019) · Medical Mycology · doi:10.1093/mmy/myy086 · Cited by 289
Bastos, R. W., Carneiro, H. C. S., Oliveira, L. V. N., Rocha, K. M., Freitas, G. J. C., Costa, M. C., Magalhães, T. F. F., Carvalho, V. S. D., Rocha, C. E., Ferreira, G. F., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01179-17 · Cited by 72
Pianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
Villanueva-Lozano, H., Treviño-Rangel, R. D. J., González, G. M., Hernández-Rodríguez, P. A., Camacho-Ortiz, A., Castillo-Reyna, L., Galindo-Alvarado, S. G., & Martínez-Reséndez, M. F. (2018) · Infection · doi:10.1007/s15010-017-1059-3 · Cited by 35
Metadata
- Authors
- Perfect, J. R., & Bicanic, T.
- Venue
- Fungal Genetics and Biology
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 78
- Pages
- 49-54
- ISSN
- 1087-1845 (ISSN-L)
- OpenAlex
- W1985214490
- Cited by
- 247
- References
- 10
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.